Are you an EPFL student looking for a semester project?
Work with us on data science and visualisation projects, and deploy your project as an app on top of GraphSearch.
Concept
UPMC Hillman Cancer Center
Summary
The UPMC Hillman Cancer Center, previously the University of Pittsburgh Cancer Institute (UPCI), is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, adjacent to UPMC Shadyside. The only NCI-designated cancer center in Western Pennsylvania, Hillman is composed of collaborative academic and research efforts between the University of Pittsburgh, the University of Pittsburgh Medical Center (UPMC), and Carnegie Mellon University. Hillman provides clinical cancer care to some 74,000 patients treated at its facilities at both the Hillman Cancer Center location in the Shadyside neighborhood of Pittsburgh and at UPMC-affiliated sites throughout Pennsylvania, New York, Ohio, and overseas locations. Founded in 1984, Hillman became the youngest cancer center in history to achieve NCI-designation. As of 2007, Hillman had received nearly $200 million in funding from the National Cancer Institute, which ranks it as one of the top ten cancer research institutes.
The Pittsburgh Cancer Institute was founded in 1985 under the direction of Ronald B. Herberman, MD. In 1990, the center earned NCI designation. The Hillman Cancer Center was opened in 2002 and housed the clinical services for UPMC Cancer Centers and research facilities for the Pittsburgh Cancer Institute. Hillman is the only NCI-designated Comprehensive Cancer Center in Western Pennsylvania.
Most Hillman faculty maintain academic appointments at the University of Pittsburgh and physician-scientists have their clinical appointments through UPMC hospitals. Some Hillman members are affiliated with the neighboring Carnegie Mellon University. Four target research areas of molecular and medical oncology at the institute include: cancer development and progression; identification of new biomarkers for improved cancer detection and diagnosis; the development of novel therapeutics for cancer treatment; and cancer prevention measures.
In 2017, Robert L.
Official source
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.